



Differentiation between Focal Malignant Marrow-Replacing Lesions and Benign Red Marrow Deposition of the Spine with T2*-Corrected Fat-Signal Fraction Map Using a Three-Echo Volume Interpolated Breath-Hold Gradient Echo Dixon Sequence

Yong Pyo Kim, MD¹, Stephan Kannengiesser, PhD², Mun-Young Paek, MS³, Sungjun Kim, MD, PhD¹, Tae-Sub Chung, MD, PhD¹, Yeon Hwa Yoo, MD¹, Choon-Sik Yoon, MD, PhD¹, Ho-Taek Song, MD, PhD⁴, Young Han Lee, MD, PhD⁴, Jin-Suck Suh, MD, PhD⁴

¹Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Korea; ²MR Applications Development, Siemens AG, Healthcare Sector, Erlangen D-91052, Germany; ³Siemens Ltd., Seoul 120-837, Korea; ⁴Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul 120-752, Korea

Objective: To assess the feasibility of T2*-corrected fat-signal fraction (FF) map by using the three-echo volume interpolated breath-hold gradient echo (VIBE) Dixon sequence to differentiate between malignant marrow-replacing lesions and benign red marrow deposition of vertebrae.

Materials and Methods: We assessed 32 lesions from 32 patients who underwent magnetic resonance imaging after being referred for assessment of a known or possible vertebral marrow abnormality. The lesions were divided into 21 malignant marrow-replacing lesions and 11 benign red marrow depositions. Three sequences for the parameter measurements were obtained by using a 1.5-T MR imaging scanner as follows: three-echo VIBE Dixon sequence for FF; conventional T1-weighted imaging for the lesion-disc ratio (LDR); pre- and post-gadolinium enhanced fat-suppressed T1-weighted images for the contrast-enhancement ratio (CER). A region of interest was drawn for each lesion for parameter measurements. The areas under the curve (AUC) of the parameters and their sensitivities and specificities at the most ideal cutoff values from receiver operating characteristic curve analysis were obtained. AUC, sensitivity, and specificity were respectively compared between FF and CER.

Results: The AUCs of FF, LDR, and CER were 0.96, 0.80, and 0.72, respectively. In the comparison of diagnostic performance between the FF and CER, the FF showed a significantly larger AUC as compared to the CER ($p = 0.030$), although the difference of sensitivity ($p = 0.157$) and specificity ($p = 0.157$) were not significant.

Conclusion: Fat-signal fraction measurement using T2*-corrected three-echo VIBE Dixon sequence is feasible and has a more accurate diagnostic performance, than the CER, in distinguishing benign red marrow deposition from malignant bone marrow-replacing lesions.

Index terms: *Magnetic resonance imaging; Spine; Fat signal fraction; Bone marrow*

Received May 10, 2014; accepted after revision August 27, 2014.

This study was supported by a faculty research grant of Yonsei University College of Medicine for 2013 (6-2013-0038).

Corresponding author: Sungjun Kim, MD, PhD, Department of Radiology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 135-720, Korea.

• Tel: (822) 2019-3510 • Fax: (822) 3462-5472 • E-mail: agn70@yuhs.ac

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

For physicians, one of the most commonly encountered scenarios during interpretation of conventional magnetic resonance (MR) imaging of the spine is differentiating neoplastic marrow infiltration from red marrow deposition (1). Several methods can be used for this differentiation, such as diffusion-weighted imaging, chemical-shift imaging, dynamic contrast-enhanced imaging, and MR spectroscopy (2, 3). In this study, we focused on chemical-shift imaging.

Normal marrow is an intermixture of hematopoietically active (red) marrow and inactive (yellow) marrow supported by varying proportions of structural trabecular bone. Red and yellow marrow possess a substantial fat component (2-5). Hence, benign red marrow deposition generally shows higher signal intensity (SI) on T1-weighted images as compared to sound muscle and the intervertebral disc (2, 3). On the other hand, the SIs of pathologic bone marrow lesions are generally similar to or lower than those of the muscle and disc because the fat-containing bone marrow of the spine is replaced by tumor cells (5-7). However, similar to pathologic bone marrow lesions, benign hypercellular red marrow may show an unexpectedly low SI on T1-weighted imaging (T1WI) (3). Many studies have tested in- and opposed-phase imaging for marrow lesion differentiation which is based on the expectation that the presence of fat in red marrow can cause the SI to drop on opposed-phase imaging (1, 5, 6, 8, 9). We thought that lesions without fat, which can be seen in marrow replacing conditions, could theoretically show no or less signal drop in the opposed phase. Hence, we commenced this study with the expectation that measurement of the fat-signal fraction (FF), considering T2* decay bias correction (10, 11), could be feasible and may be more reasonable than an indirect measurement, with opposed-phase imaging, of fat within a lesion. To the best of our knowledge, the utility of FF quantification to differentiate between malignant and benign marrow lesions has not been addressed.

Hence, the purpose of this study was to evaluate the feasibility of T2*-corrected FF quantification by using three-echo gradient echo imaging with T2* correction and Dixon water/fat separation to differentiate malignant marrow-replacing lesions from benign red marrow deposition of vertebrae.

MATERIALS AND METHODS

Patients

The Institutional Review Board reviewed our study and issued a waiver. All patients signed an informed consent as part of their research hospital visits. From March 2012 to February 2013, 46 consecutive patients, who were referred for MR imaging to evaluate a suspected spinal malignancy (n = 32) or presented with an incidentally found marrow signal abnormality (defined as low or similar signal intensity to non-degenerated intervertebral disc on T1WI) during MR imaging, were assessed for the etiology of back or neck pain (n = 14). These patients underwent an MR protocol, including a FF mapping sequence, as described below. Patients, who received radiotherapy on the marrow lesions (n = 5) or systemic chemotherapy (n = 8) prior to MR imaging, were excluded because these treatments are known to cause unpredictable signal alterations that might affect FF (6). One patient was excluded because of an uncorrectable calculation error; this error, which was found during image analysis, presumably occurred during image acquisition of the FF mapping sequence. Therefore, our study included 32 patients (17 women, 15 men; mean age, 59.9 ± 14.2 years; age range, 36-94 years) who underwent MR examination for naïve marrow lesions.

The subjects were divided into two groups; the division was based on the pathologic examination result or on the clinical and diagnostic imaging results, which were interpreted by two experienced musculoskeletal radiologists with 23 and 11 years of experience in spine imaging interpretation, respectively.

Group 1 consisted of 21 subjects whose marrow lesions were malignant marrow-replacing lesions (9 women and 12 men; mean age, 58 ± 12.8 years; age range, 36-94 years). These subjects were included in this group because of hot uptake of the lesion in 18F-fluodeoxyglucose positron emission tomographic (PET)-computed tomography (CT) (n = 9), newly developed radiopharmaceutical uptake on follow-up bone scintigraphy (n = 2), a pathologic result from CT-guided biopsy (n = 8), and from bone marrow aspiration for patients with a suspected hematologic malignancy (n = 2). The malignant marrow-replacing lesions of the subjects were as follows: lung cancer (n = 4); pancreatic cancer (n = 1); colorectal cancer (n = 4); multiple myeloma (n = 2); thyroid carcinoma (n = 2); nasopharyngeal cancer (n = 1); gall bladder adenocarcinoma (n = 1); gastric adenocarcinoma (n = 1); breast cancer (n = 2); prostate cancer (n = 2); and

hepatocellular carcinoma (n = 1).

Group 2 consisted of 11 subjects with benign red marrow depositions (3 women and 8 men; mean age, 63.6 ± 16.5 years; age range, 38–90 years). These patients were included in this group based on histology (hypercellular red marrow, n = 4) and imaging assessment results (n = 7). The imaging criteria included no size progression and morphologic change at 2-month and 6-month follow-up MRI (12, 13), no pathologic uptake with bone scan (n = 2) or PET/CT (n = 5). Other benign lesions were excluded, through CT, for all patients as follows: no coarse trabeculation to exclude hemangioma and no sclerosis to rule out lesion mineralization, which can be seen in benign notochordal cell tumor (14).

MR Imaging Protocol

MR imaging was performed on a 1.5-T MR imaging scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany) with spine matrix coils. In addition to routine sequences including sagittal T1-weighted turbo spin echo (TSE) imaging, fat-suppressed (FS) T1-weighted TSE images in the axial plane and pre- and post-gadolinium (Gd)-enhanced FS T1-weighted TSE images (contrast material, 0.1 mmol of gadoterate meglumine [Dotarem; Guerbet, Roissy, France] per kilogram of body weight) in the sagittal plane were included. For T2*-corrected FF quantification, a three-echo volume interpolated breath-hold gradient-echo sequence (VIBE-Dixon, work-in-progress 432.rev.1, Siemens Healthcare, Erlangen, Germany) was used. It enables one to sample one opposed-phase echo and two in-phase echoes. A T2* map is estimated from the latter two echoes; the opposed-phase and first in-phase echoes are then corrected for T2* effects, and they are processed by

the two-point Dixon water/fat separation algorithm. This sequence automatically reconstructs FF images. The imaging parameters of the pulse sequences used for analysis are summarized in Table 1.

Image Analysis

We obtained three parameters for one representative lesion (the largest lesion on the images), if multiple lesions were present, in each subject by using the images. The parameters were the FF, lesion-disc ratio (LDR), and contrast-enhancement ratio (CER). The FF was directly obtained by drawing a region of interest (ROI) of the lesion on the automatically reconstructed FF image obtained from the three-echo VIBE-Dixon sequence. The LDR was obtained from the following equation: $LDR = (SI \text{ of marrow lesion} / SI \text{ of disc}) \times 100$, where SI was measured from the images obtained from sagittal T1WI. In a prior report, Zhao et al. (15) described that non-degenerative disc and muscle showed similar accuracy as an internal standard to assess bone marrow pathologies in 1.5-T scanner images whereas muscle showed superior accuracy, as compared to non-degenerative disc, for the purpose in 3-T scanner images. Thus, in our study, the non-degenerative disc SI was adopted as the internal reference standard to assess marrow lesions because we used a 1.5-T MR imaging scanner. Additionally, on sagittal images, a non-degenerative disc was easier to select than non-fatty muscles. The degeneration of disc was evaluated by using Pfirrmann's grading system (16). The CER was calculated by dividing the difference between the LDR values of post- and pre-Gd-enhanced FS T1WI by the LDR value of pre-Gd-enhanced FS T1WI and according to the following equation: $CER = (LDR_{\text{post Gd-enhanced FS T1WI}} - LDR_{\text{pre Gd-enhanced FS T1WI}}) \times 100 /$

Table 1. Summary of Analyzed MR Imaging Parameters

Imaging Parameters	Sagittal T1-Weighted TSE	Sagittal FS T1-Weighted TSE	Sagittal Gd-Enhanced FS T1-Weighted TSE	Sagittal Three-Echo VIBE-Dixon
Repetition time (msec)	450	575	575	20
Echo time (msec)	10	10	10	4.76, 7.14, 9.52
Bandwidth (Hz/pixel)	199	199	199	558
Echo train length	3	3	3	1
Flip angle (°)	145	145	145	25
No. of slices	17	17	17	30
Section thickness, gap (mm)	3, 0.3	3, 0.3	3, 0.3	3, 0
Matrix size	410 × 512	410 × 512	410 × 512	192 × 256
Field of view (mm)	500 × 500	500 × 500	500 × 500	400 × 400
Imaging time	4 min, 30 sec	4 min, 50 sec	4 min, 50 sec	1 min, 10 sec

Note.— FS = fat suppressed, Gd = gadolinium, TSE = turbo spin echo, VIBE = volume interpolated breath-hold gradient echo

$LDR_{pre\ Gd-enhanced\ FS\ T1WI}$, where $LDR_{post\ Gd-enhanced\ FS\ T1WI}$ and $LDR_{pre\ Gd-enhanced\ FS\ T1WI}$ are the LDR of the lesion on enhanced and unenhanced images, respectively. The SI of a tissue on an MR image is not an absolute value because it is determined by coil loading, the receiver setting at the MR console, and image reconstruction parameters; thus, the SI value must be related to an internal standard (17). We set the intervertebral disc, which does not generally enhance with Gd, as the internal standard to measure the enhancement degree on pre- and post-Gd-enhanced FS T1WI.

To test whether the disc was enhanced, the signal-to-noise ratio (SNR) of each reference disc was estimated by dividing the SI of the disc by the standard deviation of the background SI. For this calculation, a third-year resident trainee drew the ROIs both for pre- and post-Gd-enhanced FS T1WI at the identical location of the images by copying and pasting the ROIs on an MR imaging workstation, as described below. The mean SNRs of the discs were compared between the sequences. We presumed that the disc was an appropriate internal standard. All three parameters were recorded as percentages.

A round ROI was drawn on an MR imaging workstation by using syngo MR software (VB17, Siemens Healthcare, Erlangen, Germany). The ROI for the representative lesion was drawn as large as possible without violating the adjacent marrow. The ROI for the non-degenerative disc (selected on the sagittal T2-weighted image) was drawn at the center of the nucleus pulposus, at the same image slice of the representative lesion; the ROI was drawn as large as possible and without violating the adjacent endplate. For the LDR and CER parameters, the ROI was drawn on the images from T1WI, and the ROI was copied and pasted on the corresponding images taken from pre- and post-Gd-enhanced FS T1WI in order to obtain the measurement from the identical position for each lesion. However, the ROI for the FF was drawn at the most completely matched images and with reference to the T1WI because, given the different matrix and geometry parameters, it was impossible to copy and paste the ROI (Fig. 1).

The average values of three consecutive slices in each target lesion were calculated and recorded. A third-year resident trainee and a radiologist with 11 years of experience in musculoskeletal radiology independently drew the ROIs after the subject order was randomized.

Statistical Analysis

The interobserver agreement for measuring parameter

values was assessed by using the intraclass correlation coefficient (ICC). The mean values of the parameters were used for further analyses.

By using the paired Student's *t* test, the mean SNRs of the reference discs were compared between the pre- and post-Gd-enhanced FS T1WI. In order to see if FF, LDR, and CER were affected by age and sex as previously reported (18), Spearman correlation coefficient and Mann-Whitney U test were conducted.

The median values and interquartile range of each group in each parameter were calculated for group 1 and 2. Since normality assumption was violated when we used the Shapiro-Wilk test ($p < 0.05$), we used nonparametric Mann-Whitney U test to compare the median values of the three parameters between the two groups.

Receiver operating characteristic (ROC) curves were obtained in order to evaluate the diagnostic performance of the three parameters while the sensitivities and specificities, at the most ideal cut-off values, were determined by the ROC curve. Confidence intervals for the area under the curve (AUC), sensitivity, and specificity were computed to account for sampling variation in the data. False-positive (erroneously defined as malignancy) and false-negative (erroneously defined as benign) results were counted for each parameter and were analyzed by two investigators in consensus regarding explanatory factors. For false-negative results, the pathology of the lesion was recorded. The usefulness of low signal intensity of the marrow lesions on T1WI as a tool for the differentiation between malignant and benign marrow lesions has well been validated in prior studies (19, 20), and we aimed to assess whether the FF quantification can be an additional tool for the differentiation by comparing it with CER. To compare the diagnostic performance of FF and CER, their AUCs were compared by using the DeLong test. The sensitivities and specificities of the two parameters were also compared by using McNemar's test.

All statistical analyses were performed by using SAS software (V 9.2, SAS Institute, Cary, NC, USA). *P* values < 0.05 were considered statistically significant.

RESULTS

All overall interobserver agreements between the two readers for measuring parameter values indicated perfect agreement. The ICC values for FF, LDR, and CER were 0.991, 0.997, and 0.965, respectively. The mean ROI size of the

readers was $90.0 \pm 58.6 \text{ mm}^2$ (range, 17.2–236.5 mm^2) for lesions and $22.1 \pm 19.7 \text{ mm}^2$ (range, 5.7–53.2 mm^2) for discs.

The Spearman correlation coefficient for the three parameters and age were all below 0.3 with non-significant p value (> 0.05), indicating no correlation between age and the parameters. Also, the result of the Mann-Whitney U test showed that the median values of the three parameters were not significantly different between male and female. These results advocate that age and sex would not affect

our analysis.

In the reference disc SNR enhancement assessment, the mean disc SNR of pre-Gd-enhanced FS T1WI was 44.6 ± 15.4 (range, 15.5–72.0) and that of post-Gd-enhanced FS T1WI was 43.4 ± 16.0 (range, 15.1–72.2). No difference in the SNR was observed between pre- and post-Gd-enhanced FS T1WI ($p = 0.168$), indicating that the means discs were not enhanced and could be used as an internal standard.

The median values of each parameter in each group are summarized in Table 2. All three parameters showed a




Fig. 1. Region of interest (ROI) placement and parameter measurement. Screen-captured image during ROI placement for parameter measurement of lesion and disc on workstation is shown. Images used for analysis were from fat-signal fraction (FF) mapping image from three-point Dixon volume interpolated breath-hold gradient-echo sequence (top left), T1-weighted imaging (T1WI, top right), and pre- (bottom left) and post- (bottom right) gadolinium (Gd)-enhanced fat suppressed (FS) T1WI. Details regarding ROI placement are described in text. FF was obtained from FF mapping sequence image by directly placing ROI. Lesion-disc ratio (LDR) was obtained from image of T1WI. Contrast-enhancement ratio (CER) was obtained from images of pre- and post-Gd-enhanced FS T1WI. Calculations for these parameters are described in text. Images of this capture were obtained from representative metastatic lesion from gastric cancer in 57-year-old man. FF, LDR, and CER were 9.8%, 92.1%, and 157.6%, respectively. All parameters indicated that lesion was malignant.

median difference between group 1 and 2 with statistical significance (Table 2). The AUC of each parameter, the optimal cut-off values obtained from the ROC curve, and the resultant sensitivity and specificity of each parameter are summarized in Table 3. In the analyses of false-positive and false-negative results, FF showed three false-negative results (metastases from prostate [n = 1], colon [n = 1], and breast cancer [n = 1]) (Fig. 2). LDR showed four false-positive results (one from pathologically proven hypercellular red marrow; three clinically categorized as red marrow deposition) (Fig. 3). CER showed two false-positive (both categorized as red marrow deposition clinically) (Fig. 4) and seven false-negative results (metastases from rectal [n = 2], thyroid [n = 1], nasopharyngeal [n = 1], lung [n = 1], prostate cancer [n = 1], and plasma cell myeloma [n = 1]) (Fig. 5).

In the comparison of AUCs between FF and CER, the AUC of FF was significantly higher as compared to that of CER ($p = 0.030$). In the McNemar's test for the comparison of sensitivity and specificity between FF and CER, the difference of the sensitivity ($p = 0.157$), specificity ($p = 0.157$) was not significant.

Table 2. Comparison of Median Values for Parameters between Malignant Marrow-Replacing Lesion and Benign Red Marrow Deposition Groups

Parameter	Median (IQR)	<i>P</i> *
FF		< 0.001
Group 1	12.8 (10.6–16.3)	
Group 2	37.3 (26.0–48.0)	
LDR		0.004
Group 1	91 (83.1–103.3)	
Group 2	120 (101.0–133.9)	
CER		0.038
Group 1	99.4 (87.9–110.2)	
Group 2	64 (55.6–93.7)	

Note.— *Statistical significance in difference of median values between group 1 and group 2 for each parameter. Group 1 = malignant marrow-replacing lesion, Group 2 = benign red marrow deposition. CER = contrast-enhancement ratio, FF = fat-signal fraction, IQR = interquartile range, LDR = lesion-disc ratio

Table 3. Diagnostic Performance of Each Parameter Determined through Receiver Operating Characteristic Curve Analysis

Parameter	AUC	Cutoff Values (%)*	Sensitivity (%)	Specificity (%)	<i>P</i> [†]
FF	0.961 (0.826–0.998)	≤ 16.8%	85.7 (18/21; 63.7–97.0)	100 (11/11; 71.5–100)	< 0.001
LDR	0.805 (0.627–0.923)	≤ 114.8%	100 (21/21; 83.9–100)	63.6 (7/11; 30.8–89.1)	0.002
CER	0.727 (0.542–0.869)	> 93.7%	66.7 (14/21; 43.0–85.4)	81.8 (9/11; 48.2–97.7)	0.038

Note.— Numbers in parentheses in AUC column are 95% confidence intervals. Numbers in parenthesis in sensitivity and specificity columns are counts used for calculation and 95% confidence intervals. *Lesions were considered malignant when FF was 16.8% or less, LDR was 114.8% or less, and CER was 93.7% or greater, [†]*P* value of AUC. AUC = area under receiver operating characteristic curve, CER = contrast-enhancement ratio, FF = fat-signal fraction, LDR = lesion-disc ratio

DISCUSSION

We assessed whether FF obtained from vertebral body lesions is feasible in differentiating malignant marrow-replacing lesions from benign red marrow deposition. We focused on red marrow deposition as the benign lesion. Although we used the chemical-shift imaging method utilized in the previous studies (4–7, 9, 21), we attempted to measure the FF itself, unlike these previous studies, as we thought this approach is more reasonable, as stated above. Regarding the use of marrow fat to differentiate between malignant versus benign bone marrow lesions, previous investigators focused on “signal drop” on opposed-phase imaging because they postulated the coexistence of fat and water in marrow (4–7, 9, 21), which is possible when bone marrow is not completely replaced by space-occupying lesions, would cause a signal drop in opposed-phase imaging. These investigators measured the signal drop of opposed-phase imaging and suggested variable cut-off values to differentiate between various benign and malignant vertebral lesions (Table 4). With these parameters, the sensitivity and specificity of differentiating between benign and malignant lesion were 88.8–95% and 80.4–100%, respectively (4–7, 9, 21). The sensitivity (85.7%) and specificity (100%) of FF in our study were comparable to those of previous studies that utilized chemical-shift imaging, indicating that our study did not show improvement in diagnostic performance of chemical-shift imaging as compared with previous studies. However, we believe our results unveiled the feasibility of FF as a tool for differentiation between benign and malignant focal bone marrow lesions, and further investigation with a larger study population is needed.

A high FF erroneously indicated that three lesions were benign: two sclerotic metastases from prostate or breast cancer and one from metastatic colon cancer. Zajick et al. (4) reported that some metastatic lesions showed a large signal drop on opposed-phase imaging, mimicking benign bone lesions. They attributed the variability of metastatic lesions



Fig. 2. Example of false-negative result (erroneously defined as benign) of fat-signal fraction (FF) illustrated from MR images and computed tomography (CT) image obtained from 54-year-old man.

He was referred for assessment of metastatic bone lesion of 4th lumbar (L4) vertebra from prostate cancer, which was suspected on bone scintigraphy by newly developed radiopharmaceutical uptake. Images obtained from MR imaging (FF mapping sequence (A), T1-weighted imaging (T1WI) (B), post-gadolinium-enhanced fat suppressed T1WI (C)), and non-contrast CT image (D) of L4 vertebral body are shown. FF image revealed high FF of lesion (arrow in A), which indicated considerable amount of fat. Lesion showed low signal intensity on T1WI (arrow in B), and it did not show avid enhancement (arrow in C). Because lesion newly developed during follow-up and appeared to be space-occupying lesion rather than degenerative change or osteitis related to enthesitis, it was categorized as group 1 (malignant marrow-replacing lesion) and was considered metastatic bone lesion from prostate cancer. FF, lesion-disc ratio (LDR), and contrast-enhancement ratio (CER) were calculated as 28.1%, 36.7%, and 49.5%, respectively, which shows that FF and CER erroneously indicated lesion was benign (false-negative results), whereas LDR correctly indicated lesion was malignant (true-positive result). Axial non-contrast CT image (D) revealed osteoblastic characteristics of this metastatic lesion.




Fig. 3. Example of false-positive result (erroneously defined as malignant) of lesion-disc ratio (LDR) illustrated from MR images obtained from 46-year-old woman.

She was referred for assessment of cause of back pain, and she was incidentally found to have marrow lesion of 2nd thoracic (T2) vertebra. Images obtained from fat-signal fraction (FF) mapping sequence (A), T1-weighted imaging (T1WI) (B), and post-gadolinium-enhanced fat suppressed T1WI (C) are shown. FF image revealed high FF of lesion (arrow in A), which indicated considerable amount of fat. Lesion showed low signal intensity on T1WI (arrow in B), and it did not show avid enhancement (arrow in C). Lesion almost completely replaced T2 vertebral body, and region of interest was drawn as described in text. CT-guide biopsy revealed that lesion was hypercellular red marrow (80% cellularity) without evidence of malignancy; hence, lesion was categorized as group 2 (benign red marrow deposition). FF, LDR, and contrast-enhancement ratio (CER) were calculated as 39.8%, 88.9%, and 81.5%, respectively, which shows that FF and CER correctly indicated lesion was benign (true-negative result), whereas LDR erroneously indicated lesion was malignant (false-positive result).




Fig. 4. Example of false-positive result (erroneously defined as malignant) of contrast-enhancement ratio (CER) illustrated from MR images obtained from 66-year-old woman.

She was referred for assessment of cause of back pain, and she was incidentally found to have marrow lesion of 5th lumbar (L5) vertebra. Images obtained from fat-signal fraction (FF) mapping sequence (A), T1-weighted imaging (T1WI) (B), and post-gadolinium-enhanced fat suppressed T1WI (C) of L5 vertebral body are shown. FF image showed focal lesion (arrow in A). Multifocal high FF of lesion (arrowheads in A) was observed, which indicated multifocal fat deposition. Lesion showed low signal intensity on T1WI (arrow in B), and it had relatively avid enhancement (arrow in C). Because lesion did not show morphologic or signal change on 6-month follow-up MR imaging and did not show mineralization or osteolytic lesion at corresponding area on CT scan (D), lesion was categorized as group 2 (benign red marrow deposition). FF, lesion-disc ratio (LDR), and CER were calculated as 26.0%, 101.8%, and 132.4%, respectively, which shows that LDR and CER erroneously indicated lesion was malignant (false-positive result), whereas FF correctly indicated lesion was benign (true-negative result).




Fig. 5. Example of false-negative result (erroneously defined as benign) of contrast-enhancement ratio (CER) illustrated from MR images obtained from 42-year-old man.

He was referred for assessment of metastasis at vertebral column, which was suspected on 18F-fludeoxyglucose (FDG) positron-emission tomographic (PET)-computed tomography (CT). Images obtained from fat-signal fraction (FF) mapping sequence (A), T1-weighted imaging (T1WI) (B), and post-gadolinium-enhanced fat suppressed T1WI (C) of T9 vertebral body. FF image revealed low FF of lesion (arrow in A), which indicated low amount of fat. Lesion showed low signal intensity on T1WI (arrow in B), and it did not show avid enhancement (arrow in C). Because 18F-FDG PET-CT of this patient showed multiple increased FDG uptakes of skeleton and lung, T9 vertebral lesion was categorized as group 1 (malignant marrow-replacing lesion). Lesion almost completely replaced vertebral body, and region of interest was drawn as described in text. FF, lesion-disc ratio (LDR), and CER were calculated as 12.8%, 82.5%, and 51.6%, respectively, which shows that CER erroneously indicated lesion was benign (false-negative result), whereas FF and LDR correctly indicated lesion was malignant (true-positive result).

from lytic to sclerotic states, with sclerotic lesions having lower SIs (4). Although Zajick et al. did not completely explain the reason for this observation, we believe that the two sclerotic lesions showing false-negative results in our study are consistent with it. We adopted three-echo Dixon integrated into the VIBE sequence. The Dixon technique is a well-established imaging sequence for discrimination between water and fat protons and is based on their resonant frequency difference (22). Three-echo Dixon technique has been developed to correct T2* decay due to intra-voxel static field inhomogeneity, which depends on tissue structure and chemical properties. Three-echo Dixon has been proven to provide highly reproducible and accurate results in fat quantification (23) as compared with two-echo Dixon without T2* correction.

Even with correction of T2* effects, FF quantification may be confounded by other effects, like the multi-spectral nature of fat (24). As a result, the three-echo VIBE-Dixon sequence may produce errors similar to those observed in previous studies that utilized other chemical-shift imaging techniques, and this topic should be investigated further. However, we have no plausible explanation for the false-negative result for colon cancer metastasis in our study.

Hypothetically, the FF values for malignant marrow-

replacing lesions should be near 0% because the lesion replaces bone marrow. However, the FF cut-off value for differentiation between malignant marrow-replacing lesions and benign red marrow deposition was unexpectedly high in our study (16.8%). Although many previous studies assessed the liver rather than bone marrow, it is known that the T1 and T2* effects should be minimized to measure FF accurately because all MR signals are subject to T1 and T2/T2* relaxation (11). We believe the T2* effect was minimized in our study because we adopted a sequence that corrects the effect of T2* decay, by using signals at three different echo times, which was validated in a prior report (10). However, the 25° flip angle used in our study might have produced the T1 effect, which is known to cause FF overestimation. Cassidy et al. (11) recommended a flip angle of 5–10° and a repetition time of ≤ 100 msec to minimize the T1 effect for liver fat quantification; the sequence parameters that minimize the T1 effect for bone marrow might be different from these parameters, but we could not find any related references. Hence, we optimized our sequence empirically, and we could not minimize the flip angle to < 25°, which would have assured an appropriate image quality with respect to the SNR at the commencement of our study. We believe 25°

Table 4. Summary of Previous Studies Related to Chemical-Shift Imaging for Differentiation between Benign and Malignant Lesions

Study	Total Number of Patients (Lesions)*	Lesions That Were Differentiated [†]	Parameter	Suggested Cut-Off Value [‡]	Sensitivity	Specificity
Disler et al. (9)	30 patients (31)	Non-neoplastic lesion (14) Neoplastic lesion (17)	SI ratio ($SI_{\text{opposed-phase}}/SI_{\text{in-phase}}$)	> 0.81	95%	95%
Zampa et al. (7)	86 patients (86)	Benign lesion (41) Malignant lesion (45) Normal vertebrae (90)	SI ratio ($SI_{\text{opposed-phase}}/SI_{T1WI}$)	> 1.2	88.8%	80.4%
Eito et al. (21)	108 patients (190)	Compression fracture (100) Non-neoplastic (73) Neoplastic (27)	SI ratio ($SI_{\text{opposed-phase}}/SI_{\text{in-phase}}$)	None [§]	N/A	N/A
Zajick et al. (4)	75 patients (569) 92 patients (215)	Normal vertebrae (569) Benign lesion (164) Malignant lesion (51)	% decrease of $SI_{\text{opposed-phase}}$ compared with $SI_{\text{in-phase}}$	≤ 20%	N/A	N/A
Erlly et al. (6)	21 patients (49)	Benign compression fracture (29) Malignant lesion (20)	SI ratio ($SI_{\text{opposed-phase}}/SI_{\text{in-phase}}$)	> 0.8	95%	89%
Ragab et al. (5)	40 patients (40)	Compression fracture (40) Osteoporotic (20) Neoplastic (20)	% decrease of $SI_{\text{opposed-phase}}$ compared with $SI_{\text{in-phase}}$	≤ 35%	95%	100%

Note.— *Numbers in parentheses in this column are counts of lesions, [†]Normal, benign, and malignant lesions that were described and assessed. Numbers in parentheses of this column are counts of lesions, [‡]Lesions were defined as malignant when suggested cut-off value was satisfied for each parameter, [§]Eito et al. calculated mean value of each lesion group, but did not estimate cut-off value for differentiating between groups. N/A = not available, SI = signal intensity, $SI_{\text{in-phase}}$ = signal intensity of in-phase image, $SI_{\text{opposed-phase}}$ = signal intensity of opposed-phase image, SI_{T1WI} = signal intensity of T1-weighted image

was not adequate for minimizing the T1 effect, given the unexpectedly high FF of our study. Further validation of FF quantification sequences is needed. T1 effect reduction could be achieved by using a more accurate correction of the confounding T2* effect and multi-spectral fat nature, by using signals from more echo time points, and using a low flip angle.

The sensitivity and specificity of T1WI in previous studies that were performed with 1.5-T scanners were 62.5–100% and 92–93.8% for differentiating benign and malignant lesions, respectively (15, 20). Although the sensitivity of our study was comparable to that of these studies, the specificity was far lower due to different analysis methods (20) and the selection of benign subjects for comparison (15). Nevertheless, LDR is a sensitive method in daily practice for detection or screening of marrow signal abnormality, and we do not believe that our study supports that FF can replace LDR in that regard. Rather, we expect that the FF would play a complementary role for additional differentiation with its high specificity, which would be superior to CER, since CER showed poorer performance when compared to FF in our study. Gd-enhanced MR imaging needed to be compared with the FF measurement in the performance of differentiation between benign and malignant marrow lesions because previous studies have already elucidated its usefulness in this aspect (13, 25, 26).

Our study had several limitations. First, the small number of study subjects might have biased our results. Second, the pulse sequence for FF quantification was not validated through a bone marrow phantom because this is technically difficult. However, we have elucidated that a T2*-corrected FF map by using the three-echo VIBE-Dixon sequence, which is at least feasible for differentiating between malignant marrow-replacing lesions and benign red marrow deposition of vertebrae. Third, not all assessed lesions were pathologically proven because it would be unethical to biopsy lesions with a high probability of malignancy or benignancy in a clinical setting. Fourth, we adopted only LDR for the parameters on T1WI, although qualitative assessment of imaging findings (e.g., bull's eye sign) (27) is useful for differentiating between malignant and benign bone lesions. This reason may also explain why the specificity of T1WI was lower than expected in our study. However, this qualitative assessment was beyond the scope of our study.

In conclusion, T2*-corrected FF measurement using a three-echo VIBE-Dixon sequence is feasible and is expected

to play a complementary role for distinguishing benign red marrow deposition from malignant bone marrow-replacing lesions of vertebrae.

REFERENCES

- Swartz PG, Roberts CC. Radiological reasoning: bone marrow changes on MRI. *AJR Am J Roentgenol* 2009;193(3 Suppl):S1-S4, Quiz S5-S9
- Shah LM, Hanrahan CJ. MRI of spinal bone marrow: part I, techniques and normal age-related appearances. *AJR Am J Roentgenol* 2011;197:1298-1308
- Tall MA, Thompson AK, Vertinsky T, Palka PS. MR imaging of the spinal bone marrow. *Magn Reson Imaging Clin N Am* 2007;15:175-198, vi
- Zajick DC Jr, Morrison WB, Schweitzer ME, Parellada JA, Carrino JA. Benign and malignant processes: normal values and differentiation with chemical shift MR imaging in vertebral marrow. *Radiology* 2005;237:590-596
- Ragab Y, Emad Y, Gheita T, Mansour M, Abou-Zeid A, Ferrari S, et al. Differentiation of osteoporotic and neoplastic vertebral fractures by chemical shift {in-phase and out-of phase} MR imaging. *Eur J Radiol* 2009;72:125-133
- Erly WK, Oh ES, Outwater EK. The utility of in-phase/opposed-phase imaging in differentiating malignancy from acute benign compression fractures of the spine. *AJNR Am J Neuroradiol* 2006;27:1183-1188
- Zampa V, Cosottini M, Michelassi C, Ortori S, Bruschini L, Bartolozzi C. Value of opposed-phase gradient-echo technique in distinguishing between benign and malignant vertebral lesions. *Eur Radiol* 2002;12:1811-1818
- Wisner GL, Rosen BR, Buxton R, Stark DD, Brady TJ. Chemical shift imaging of bone marrow: preliminary experience. *AJR Am J Roentgenol* 1985;145:1031-1037
- Disler DG, McCauley TR, Ratner LM, Kesack CD, Cooper JA. In-phase and out-of-phase MR imaging of bone marrow: prediction of neoplasia based on the detection of coexistent fat and water. *AJR Am J Roentgenol* 1997;169:1439-1447
- Kühn JP, Evert M, Friedrich N, Kannengiesser S, Mayerle J, Thiel R, et al. Noninvasive quantification of hepatic fat content using three-echo dixon magnetic resonance imaging with correction for T2* relaxation effects. *Invest Radiol* 2011;46:783-789
- Cassidy FH, Yokoo T, Aganovic L, Hanna RF, Bydder M, Middleton MS, et al. Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. *Radiographics* 2009;29:231-260
- Geith T, Schmidt G, Biffar A, Dietrich O, Dürr HR, Reiser M, et al. Comparison of qualitative and quantitative evaluation of diffusion-weighted MRI and chemical-shift imaging in the differentiation of benign and malignant vertebral body fractures. *AJR Am J Roentgenol* 2012;199:1083-1092
- Chen WT, Shih TT, Chen RC, Lo HY, Chou CT, Lee JM, et al. Blood perfusion of vertebral lesions evaluated with

- gadolinium-enhanced dynamic MRI: in comparison with compression fracture and metastasis. *J Magn Reson Imaging* 2002;15:308-314
14. Yamaguchi T, Iwata J, Sugihara S, McCarthy EF Jr, Karita M, Murakami H, et al. Distinguishing benign notochordal cell tumors from vertebral chordoma. *Skeletal Radiol* 2008;37:291-299
 15. Zhao J, Krug R, Xu D, Lu Y, Link TM. MRI of the spine: image quality and normal-neoplastic bone marrow contrast at 3 T versus 1.5 T. *AJR Am J Roentgenol* 2009;192:873-880
 16. Pfirrmann CW, Metzdorf A, Zanetti M, Hodler J, Boos N. Magnetic resonance classification of lumbar intervertebral disc degeneration. *Spine (Phila Pa 1976)* 2001;26:1873-1878
 17. Buckley DL, Parker GJM. *Measuring contrast agent concentration in T1-weighted dynamic contrast-enhanced MRI*. In: Jackson A, Buckley DL, Parker GJM, eds. *Dynamic contrast-enhanced magnetic resonance imaging in oncology*, 1st ed. Berlin, London: Springer, 2004:69-79
 18. Griffith JF, Yeung DK, Ma HT, Leung JC, Kwok TC, Leung PC. Bone marrow fat content in the elderly: a reversal of sex difference seen in younger subjects. *J Magn Reson Imaging* 2012;36:225-230
 19. Vande Berg BC, Malghem J, Lecouvet FE, Maldague B. Classification and detection of bone marrow lesions with magnetic resonance imaging. *Skeletal Radiol* 1998;27:529-545
 20. Carroll KW, Feller JF, Tirman PF. Useful internal standards for distinguishing infiltrative marrow pathology from hematopoietic marrow at MRI. *J Magn Reson Imaging* 1997;7:394-398
 21. Eito K, Waka S, Naoko N, Makoto A, Atsuko H. Vertebral neoplastic compression fractures: assessment by dual-phase chemical shift imaging. *J Magn Reson Imaging* 2004;20:1020-1024
 22. Dixon WT. Simple proton spectroscopic imaging. *Radiology* 1984;153:189-194
 23. Kovanlikaya A, Guclu C, Desai C, Becerra R, Gilsanz V. Fat quantification using three-point dixon technique: in vitro validation. *Acad Radiol* 2005;12:636-639
 24. Reeder SB, Bice EK, Yu H, Hernando D, Pineda AR. On the performance of T2* correction methods for quantification of hepatic fat content. *Magn Reson Med* 2012;67:389-404
 25. Rahmouni A, Divine M, Mathieu D, Golli M, Dao TH, Jazaerli N, et al. Detection of multiple myeloma involving the spine: efficacy of fat-suppression and contrast-enhanced MR imaging. *AJR Am J Roentgenol* 1993;160:1049-1052
 26. Breault SR, Heye T, Bashir MR, Dale BM, Merkle EM, Reiner CS, et al. Quantitative dynamic contrast-enhanced MRI of pelvic and lumbar bone marrow: effect of age and marrow fat content on pharmacokinetic parameter values. *AJR Am J Roentgenol* 2013;200:W297-W303
 27. Schweitzer ME, Levine C, Mitchell DG, Gannon FH, Gomella LG. Bull's-eyes and halos: useful MR discriminators of osseous metastases. *Radiology* 1993;188:249-252